Pfizer: Covid-19 vaccine advances into late-stage trial

(CercleFinance.com) - Pfizer and its German partner BioNTech said that they will start a Phase 2/3 clinical trials of BNT162, the Covid-19 vaccine program they have chosen to advance.


The companies said they have selected BNT162b2 as the candidate to progress, based on available data from preclinical and clinical studies, including immune response and tolerability parameters.

The late-stage global study will include up to 30,000 participants.

If the trial proves successful, Pfizer and BioNTech expect to be ready to seek emergency use authorization or some form of regulatory approval as early as October 2020.

Copyright (c) 2020 CercleFinance.com. All rights reserved.